Isthmus Partners LLC Sells 320 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Isthmus Partners LLC reduced its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 3.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,630 shares of the company’s stock after selling 320 shares during the quarter. Isthmus Partners LLC’s holdings in Henry Schein were worth $652,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. purchased a new position in shares of Henry Schein during the fourth quarter valued at about $39,000. Mather Group LLC. bought a new position in Henry Schein in the 1st quarter valued at $97,000. Palisade Asset Management LLC purchased a new position in Henry Schein in the 1st quarter worth about $113,000. Benjamin F. Edwards & Company Inc. grew its stake in Henry Schein by 37.8% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,516 shares of the company’s stock worth $114,000 after purchasing an additional 416 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in Henry Schein in the fourth quarter worth approximately $115,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Henry Schein stock traded up $1.75 during midday trading on Tuesday, reaching $67.59. 1,606,427 shares of the company were exchanged, compared to its average volume of 1,079,582. Henry Schein, Inc. has a 1 year low of $60.01 and a 1 year high of $82.63. The firm’s 50-day simple moving average is $68.60 and its 200-day simple moving average is $72.12. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. The company has a market capitalization of $8.65 billion, a price-to-earnings ratio of 22.56, a P/E/G ratio of 1.61 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.09. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.21 billion. During the same period in the previous year, the firm earned $1.21 earnings per share. Henry Schein’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts anticipate that Henry Schein, Inc. will post 5.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HSIC. UBS Group dropped their target price on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, May 8th. Piper Sandler reissued an “overweight” rating and set a $86.00 price objective on shares of Henry Schein in a report on Friday, June 21st. Barrington Research restated an “outperform” rating and set a $92.00 target price on shares of Henry Schein in a report on Friday, July 5th. Finally, Evercore ISI cut their price target on Henry Schein from $75.00 to $72.00 and set an “in-line” rating on the stock in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $80.73.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.